The private biopharmaceutical company, Aculys Pharma, is launching a phase III therapeutic trial for excessive daytime sleepiness (EDS).<\/p>\n
The test patients in this trial have obstructive sleep apnea syndrome (OSA) and complain of EDS. This is manifested by upper airway obstruction, coupled with fatigue, drowsiness and an overall lack of energy.<\/p>\n
The trial aims to evaluate the efficacy and safety of the drug, which has already been approved by the US Food and Drug Administration (FDA) for the treatment of EDS associated with narcolepsy.<\/p>\n
In addition, Aculys Pharma announced a research collaboration with Four H, which uses wearable devices to help patients with narcolepsy and EDS associated with OSA in Japan.<\/p>\n","protected":false},"excerpt":{"rendered":"
The private biopharmaceutical company, Aculys Pharma, is launching a phase III therapeutic trial for excessive daytime sleepiness (EDS). The test patients in this trial have obstructive sleep apnea syndrome (OSA) and complain of EDS. This is manifested by upper airway obstruction, coupled with fatigue, drowsiness and an overall lack of energy. The trial aims to […]<\/p>\n","protected":false},"author":1,"featured_media":979,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[18],"tags":[],"class_list":["post-978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-conference-en"],"acf":[],"yoast_head":"\n